HQY logoHQY
Healthequity Inc

1,808
Loading...
Loading...
News
all
press releases
HealthEquity Stock Gains as Q2 Earnings Beat Estimates, Revenues Up Y/Y
HQY's Q2 results reflect EPS growth of 25.6% year over year, revenue growth of 8.6% and a 12% increase in HSA. The company also updates its fiscal 2026 guidance.
Zacks·4d ago
News Placeholder
More News
News Placeholder
Compared to Estimates, HealthEquity (HQY) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for HealthEquity (HQY) give a sense of how its business performed in the quarter ended July 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·5d ago
News Placeholder
HealthEquity (HQY) Q2 Earnings and Revenues Surpass Estimates
HealthEquity (HQY) delivered earnings and revenue surprises of +17.39% and +2.20%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
CVS vs. HQY: Which Stock Is the Better Value Option?
CVS vs. HQY: Which Stock Is the Better Value Option?
Zacks·11d ago
News Placeholder
Countdown to HealthEquity (HQY) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Get a deeper insight into the potential performance of HealthEquity (HQY) for the quarter ended July 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Zacks·11d ago
News Placeholder
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates
RenovoRx (RNXT) delivered earnings and revenue surprises of 0.00% and +22.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·24d ago
News Placeholder
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HQY's HSA growth, AI-driven efficiencies, and strong Q1 results fuel optimism despite data security concerns.
Zacks·24d ago
News Placeholder
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +52.00% and -12.13%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·25d ago
News Placeholder
OGN vs. HQY: Which Stock Is the Better Value Option?
OGN vs. HQY: Which Stock Is the Better Value Option?
Zacks·1mo ago
News Placeholder
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
Biodesix (BDSX) delivered earnings and revenue surprises of -14.29% and +7.34%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago

Latest HQY News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.